Aquestive Therapeutics (AQST) EBIT Margin (2017 - 2026)

Aquestive Therapeutics' EBIT Margin history runs 10 years deep, the most recent figure standing at 29.1% for Q1 2026.

• In Q1 2026, EBIT Margin rose 19297.0% year-over-year to 29.1%; the TTM figure through Mar 2026 stood at 838.69% (down 76275.0% YoY), while the FY2025 annual figure was 7574.73%, down 752128.0% from the prior year.
• EBIT Margin was 29.1% for Q1 2026 at Aquestive Therapeutics, down from 94.27% in the prior quarter.
• In the past five years, EBIT Margin ranged from a high of 94.27% in Q4 2025 to a low of 222.08% in Q1 2025.
• Historically, EBIT Margin has averaged 67.49% across 5 years, with a median of 74.31% in 2024.
• Biggest YoY gain for EBIT Margin was 20870 bps in 2025; the steepest drop was 14776 bps in 2025.
• A 5-year view of EBIT Margin shows it stood at 100.29% in 2022, then surged by 70 bps to 29.62% in 2023, then tumbled by 286 bps to 114.43% in 2024, then jumped by 182 bps to 94.27% in 2025, then plunged by 131 bps to 29.1% in 2026.
• The last three EBIT Margin figures came in at 29.1% (Q1 2026), 94.27% (Q4 2025), and 89.63% (Q3 2025), per Business Quant data.